Friday, July 10, 2026

pharma · Pulmonary Hypertension Associated with Interstitial Lung Disease · Pulmonary Arterial Hypertension

Insmed Incorporated

Insmed is a pharma organization headquartered in GB. Primary therapeutic focus areas include Pulmonary Hypertension Associated with Interstitial Lung Disease, Pulmonary Arterial Hypertension, Chronic Rhinosinusitis witho

Bridgewater Township, USA HQ
1,666 Employees
EMA registrant Type
Company details
Status
Public
HQ
Bridgewater Township, USA
Employees
1,666
Programs
7
Drugs
18
Patents
0
Clinical program

INS1009-203

Phase 3 · small molecule · Pulmonary Arterial Hypertension

INS1009-203 for Pulmonary Arterial Hypertension is a Phase 3 program (small_molecule) at Insmed Limited with 1 ClinicalTrials.gov record(s).

← All Insmed Limited projects Phase 3 small molecule active

Internal code INS1009-203

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Insmed Limited
Phase
Phase 3
Modality
small_molecule
Indication
Pulmonary Arterial Hypertension
Status
active
Trials
1